|
Gene: MAFB |
Gene summary for MAFB |
Gene summary. |
Gene information | Species | Human | Gene symbol | MAFB | Gene ID | 9935 |
Gene name | MAF bZIP transcription factor B | |
Gene Alias | DURS3 | |
Cytomap | 20q12 | |
Gene Type | protein-coding | GO ID | GO:0001775 | UniProtAcc | Q9Y5Q3 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
9935 | MAFB | GSM4909280 | Human | Breast | Precancer | 5.81e-04 | 7.33e-01 | 0.0305 |
9935 | MAFB | GSM4909282 | Human | Breast | IDC | 1.48e-27 | 7.71e-01 | -0.0288 |
9935 | MAFB | GSM4909286 | Human | Breast | IDC | 7.83e-11 | -3.72e-01 | 0.1081 |
9935 | MAFB | GSM4909287 | Human | Breast | IDC | 6.96e-03 | -3.06e-01 | 0.2057 |
9935 | MAFB | GSM4909296 | Human | Breast | IDC | 9.99e-03 | -2.58e-01 | 0.1524 |
9935 | MAFB | GSM4909298 | Human | Breast | IDC | 3.44e-02 | -3.73e-02 | 0.1551 |
9935 | MAFB | GSM4909301 | Human | Breast | IDC | 5.15e-08 | -3.22e-01 | 0.1577 |
9935 | MAFB | GSM4909311 | Human | Breast | IDC | 7.05e-10 | -3.48e-01 | 0.1534 |
9935 | MAFB | GSM4909312 | Human | Breast | IDC | 1.11e-02 | -2.89e-01 | 0.1552 |
9935 | MAFB | GSM4909319 | Human | Breast | IDC | 1.68e-09 | -3.62e-01 | 0.1563 |
9935 | MAFB | brca2 | Human | Breast | Precancer | 5.07e-03 | -2.51e-01 | -0.024 |
9935 | MAFB | brca10 | Human | Breast | Precancer | 3.81e-04 | -3.31e-01 | -0.0029 |
9935 | MAFB | P1 | Human | Breast | IDC | 1.33e-06 | -3.05e-01 | 0.1527 |
9935 | MAFB | DCIS2 | Human | Breast | DCIS | 1.05e-38 | 9.93e-02 | 0.0085 |
9935 | MAFB | AEH-subject1 | Human | Endometrium | AEH | 1.96e-28 | 7.92e-01 | -0.3059 |
9935 | MAFB | AEH-subject2 | Human | Endometrium | AEH | 7.96e-15 | 5.48e-01 | -0.2525 |
9935 | MAFB | AEH-subject3 | Human | Endometrium | AEH | 1.77e-11 | 4.55e-01 | -0.2576 |
9935 | MAFB | EEC-subject2 | Human | Endometrium | EEC | 1.74e-06 | 3.53e-01 | -0.2607 |
9935 | MAFB | EEC-subject3 | Human | Endometrium | EEC | 1.04e-06 | -1.35e-01 | -0.2525 |
9935 | MAFB | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 5.40e-03 | -4.65e-02 | -0.1869 |
Page: 1 2 3 4 5 6 7 8 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004564625 | Thyroid | ATC | regulation of erythrocyte differentiation | 27/6293 | 47/18723 | 6.69e-04 | 3.77e-03 | 27 |
GO:00485688 | Thyroid | ATC | embryonic organ development | 172/6293 | 427/18723 | 2.08e-03 | 9.84e-03 | 172 |
GO:1903706112 | Thyroid | ATC | regulation of hemopoiesis | 148/6293 | 367/18723 | 3.87e-03 | 1.68e-02 | 148 |
GO:0045637113 | Thyroid | ATC | regulation of myeloid cell differentiation | 89/6293 | 210/18723 | 4.75e-03 | 1.96e-02 | 89 |
GO:004853813 | Thyroid | ATC | thymus development | 23/6293 | 45/18723 | 1.14e-02 | 4.06e-02 | 23 |
GO:0002573110 | Thyroid | ATC | myeloid leukocyte differentiation | 86/6293 | 208/18723 | 1.15e-02 | 4.11e-02 | 86 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0492816 | Esophagus | ESCC | Parathyroid hormone synthesis, secretion and action | 66/4205 | 106/8465 | 5.86e-03 | 1.47e-02 | 7.51e-03 | 66 |
hsa0492817 | Esophagus | ESCC | Parathyroid hormone synthesis, secretion and action | 66/4205 | 106/8465 | 5.86e-03 | 1.47e-02 | 7.51e-03 | 66 |
hsa0492810 | Lung | IAC | Parathyroid hormone synthesis, secretion and action | 26/1053 | 106/8465 | 4.34e-04 | 4.03e-03 | 2.68e-03 | 26 |
hsa0492811 | Lung | IAC | Parathyroid hormone synthesis, secretion and action | 26/1053 | 106/8465 | 4.34e-04 | 4.03e-03 | 2.68e-03 | 26 |
hsa0492814 | Prostate | BPH | Parathyroid hormone synthesis, secretion and action | 33/1718 | 106/8465 | 5.30e-03 | 1.75e-02 | 1.08e-02 | 33 |
hsa0492815 | Prostate | BPH | Parathyroid hormone synthesis, secretion and action | 33/1718 | 106/8465 | 5.30e-03 | 1.75e-02 | 1.08e-02 | 33 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAFB | SNV | Missense_Mutation | novel | c.28G>A | p.Glu10Lys | p.E10K | Q9Y5Q3 | protein_coding | deleterious(0.03) | benign(0.006) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
MAFB | SNV | Missense_Mutation | novel | c.107T>C | p.Leu36Pro | p.L36P | Q9Y5Q3 | protein_coding | deleterious(0.02) | benign(0.003) | TCGA-AR-A1AJ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MAFB | insertion | In_Frame_Ins | novel | c.880_881insCTCACCCCATGGCCAATGGAATAGCAA | p.Tyr294delinsSerHisProMetAlaAsnGlyIleAlaAsn | p.Y294delinsSHPMANGIAN | Q9Y5Q3 | protein_coding | TCGA-AO-A03T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | ||
MAFB | deletion | Frame_Shift_Del | novel | c.327delN | p.Ala110ArgfsTer115 | p.A110Rfs*115 | Q9Y5Q3 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
MAFB | SNV | Missense_Mutation | c.801G>C | p.Glu267Asp | p.E267D | Q9Y5Q3 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR | |
MAFB | SNV | Missense_Mutation | c.206N>G | p.Ser69Trp | p.S69W | Q9Y5Q3 | protein_coding | deleterious(0.01) | possibly_damaging(0.761) | TCGA-MY-A5BF-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | CR | |
MAFB | SNV | Missense_Mutation | c.229N>A | p.Glu77Lys | p.E77K | Q9Y5Q3 | protein_coding | deleterious(0.03) | benign(0.108) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
MAFB | SNV | Missense_Mutation | c.296N>T | p.Ala99Val | p.A99V | Q9Y5Q3 | protein_coding | tolerated(0.12) | benign(0.267) | TCGA-AA-3994-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | capecitabine | CR | |
MAFB | SNV | Missense_Mutation | novel | c.373G>A | p.Asp125Asn | p.D125N | Q9Y5Q3 | protein_coding | deleterious(0.04) | benign(0.188) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
MAFB | insertion | Frame_Shift_Ins | novel | c.882dupC | p.Lys295GlnfsTer51 | p.K295Qfs*51 | Q9Y5Q3 | protein_coding | TCGA-AG-4022-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
9935 | MAFB | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | Tumor necrosis factor alpha (TNF-alpha) inhibitors |
Page: 1 |